Literature DB >> 11729225

Blood pressure-independent additive effects of pharmacologic blockade of the renin-angiotensin and endothelin systems on progression in a low-renin model of renal damage.

Kerstin Amann1, Aurelia Simonaviciene1, Tatiana Medwedewa1, Andreas Koch1, Stephan Orth1, Marie-Luise Gross1, Christian Haas1, Alexander Kuhlmann1, Wolfgang Linz1, Bernward Schölkens1, Eberhard Ritz1.   

Abstract

Pharmacologic blockade of the renin and endothelin (ET) systems is an established strategy to interfere with progression of renal failure. In the Heyman nephritis model, additive benefits of decreases in BP with the combination of angiotensin-converting enzyme inhibitors (ACE-i) and ET(A) receptor antagonists (ET-RA) were demonstrated. To further investigate these findings and to exclude confounding effects of BP decreases, this issue was reassessed in a low-renin model of subtotal kidney resection. Subtotally nephrectomized (SNX) and sham-operated rats were left untreated or received an ACE-i, an angiotensin II subtype 1 receptor antagonist (AT1-RA), an ET-RA, or combinations thereof (ACE-i plus ET-RA or AT1-RA plus ET-RA). The parameters studied were the glomerulosclerosis index (GSI), tubulointerstitial index, vascular damage index, glomerular geometry, and albumin excretion. After 12 wk, BP values were comparable. Urinary albumin excretion rates were significantly higher for untreated SNX rats (24.3 +/- 31.3 mg/24 h), compared with untreated sham-operated rats (0.71 +/- 0.40 mg/24 h). Rates were significantly lower for all treated, compared with untreated, SNX groups. GSI values were significantly higher for untreated SNX rats than for untreated sham-operated rats. ACE-i caused significantly lower GSI in SNX rats (0.46 +/- 0.06), compared with AT1-RA (0.60 +/- 0.10) or ET-RA (0.65 +/- 0.10). GSI values were significantly decreased further with ACE-i plus ET-RA (0.29 +/- 0.09) or AT1-RA plus ET-RA (23 +/- 0.05) treatment. Changes in the tubulointerstitial index and vascular damage index proceeded in parallel. The results document BP-independent effects of the ACE-i and AT1-RA on the GSI and urinary albumin excretion and an effect of the ET-RA on the GSI. The contrasting results suggest different pathogenetic pathways for glomerulosclerosis and albuminuria. The combination of treatments provided superior effects on the GSI and tubulointerstitial index but not on urinary albumin excretion.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11729225     DOI: 10.1681/ASN.V12122572

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  10 in total

1.  Endothelin receptor antagonists in proteinuric renal disease: every rose has its thorn.

Authors:  Eberhard Ritz; René Wenzel
Journal:  J Am Soc Nephrol       Date:  2010-02-04       Impact factor: 10.121

2.  Reduced cardiac expression of plasminogen activator inhibitor 1 and transforming growth factor beta1 in obese Zucker rats by perindopril.

Authors:  J E Toblli; G Cao; G DeRosa; P Forcada
Journal:  Heart       Date:  2005-01       Impact factor: 5.994

Review 3.  Endothelin-1 and the kidney--beyond BP.

Authors:  Neeraj Dhaun; David J Webb; David C Kluth
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

4.  Avosentan reduces albumin excretion in diabetics with macroalbuminuria.

Authors:  René R Wenzel; Thomas Littke; Susan Kuranoff; Christiane Jürgens; Heike Bruck; Eberhard Ritz; Thomas Philipp; Anna Mitchell
Journal:  J Am Soc Nephrol       Date:  2009-01-14       Impact factor: 10.121

5.  Effects of chronotherapy of benazepril on the diurnal profile of RAAS and clock genes in the kidney of 5/6 nephrectomy rats.

Authors:  Xiao-Mei Huang; Jing-Ping Yuan; Xing-Ruo Zeng; Cai-Xia Peng; Qi-Hui Mei; Wen-Li Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2013-06-17

Review 6.  Angiotensin II and progressive renal insufficiency.

Authors:  Jens Gaedeke; Nancy A Noble; Wayne A Border
Journal:  Curr Hypertens Rep       Date:  2002-10       Impact factor: 5.369

7.  TRC120038, a Novel Dual AT(1)/ET(A) Receptor Blocker for Control of Hypertension, Diabetic Nephropathy, and Cardiomyopathy in ob-ZSF1 Rats.

Authors:  Anookh Mohanan; Ram Gupta; Amita Dubey; Vikrant Jagtap; Appaji Mandhare; Ramesh C Gupta; Vijay Chauthaiwale; Chaitanya Dutt
Journal:  Int J Hypertens       Date:  2011-12-22       Impact factor: 2.420

Review 8.  Endothelin-targeted new treatments for proteinuric and inflammatory glomerular diseases: focus on the added value to anti-renin-angiotensin system inhibition.

Authors:  Ariela Benigni; Simona Buelli; Donald E Kohan
Journal:  Pediatr Nephrol       Date:  2020-03-17       Impact factor: 3.714

9.  Endothelin receptor a blockade is an ineffective treatment for adriamycin nephropathy.

Authors:  Roderick J Tan; Lili Zhou; Dong Zhou; Lin Lin; Youhua Liu
Journal:  PLoS One       Date:  2013-11-12       Impact factor: 3.240

Review 10.  Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney disease.

Authors:  Radko Komers; Horacio Plotkin
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2016-03-23       Impact factor: 3.619

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.